JP6203372B2 - サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子 - Google Patents

サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子 Download PDF

Info

Publication number
JP6203372B2
JP6203372B2 JP2016500564A JP2016500564A JP6203372B2 JP 6203372 B2 JP6203372 B2 JP 6203372B2 JP 2016500564 A JP2016500564 A JP 2016500564A JP 2016500564 A JP2016500564 A JP 2016500564A JP 6203372 B2 JP6203372 B2 JP 6203372B2
Authority
JP
Japan
Prior art keywords
sarcin
modified
mutation
molecule
ribotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016500564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512251A (ja
JP2016512251A5 (enExample
Inventor
カート アール． ゲールセン
カート アール． ゲールセン
ティモシー デイビッド ジョーンズ
ティモシー デイビッド ジョーンズ
フランシス ジョセフ カー
フランシス ジョセフ カー
アーロン ハーン
アーロン ハーン
Original Assignee
リサーチ コーポレーション テクノロジーズ インコーポレイテッド
リサーチ コーポレーション テクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ コーポレーション テクノロジーズ インコーポレイテッド, リサーチ コーポレーション テクノロジーズ インコーポレイテッド filed Critical リサーチ コーポレーション テクノロジーズ インコーポレイテッド
Publication of JP2016512251A publication Critical patent/JP2016512251A/ja
Publication of JP2016512251A5 publication Critical patent/JP2016512251A5/ja
Application granted granted Critical
Publication of JP6203372B2 publication Critical patent/JP6203372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/2701—Endoribonucleases producing 3'-phosphomonoesters (3.1.27) rRNA endonuclease (3.1.27.10)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016500564A 2013-03-14 2014-03-03 サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子 Active JP6203372B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361783589P 2013-03-14 2013-03-14
US61/783,589 2013-03-14
US201361902972P 2013-11-12 2013-11-12
US61/902,972 2013-11-12
PCT/US2014/020035 WO2014158770A1 (en) 2013-03-14 2014-03-03 Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Publications (3)

Publication Number Publication Date
JP2016512251A JP2016512251A (ja) 2016-04-25
JP2016512251A5 JP2016512251A5 (enExample) 2017-04-06
JP6203372B2 true JP6203372B2 (ja) 2017-09-27

Family

ID=51625052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500564A Active JP6203372B2 (ja) 2013-03-14 2014-03-03 サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子

Country Status (11)

Country Link
US (2) US9603911B2 (enExample)
EP (1) EP2971038B1 (enExample)
JP (1) JP6203372B2 (enExample)
AU (1) AU2014241891B2 (enExample)
CA (1) CA2903252C (enExample)
DK (1) DK2971038T3 (enExample)
ES (1) ES2765302T3 (enExample)
PL (1) PL2971038T3 (enExample)
PT (1) PT2971038T (enExample)
SI (1) SI2971038T1 (enExample)
WO (1) WO2014158770A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603911B2 (en) * 2013-03-14 2017-03-28 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2017053290A1 (en) * 2015-09-23 2017-03-30 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
WO2020118192A1 (en) * 2018-12-07 2020-06-11 Genome Protection, Inc. Engineered flagellin-derived compositions and uses
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
US8114969B2 (en) 2003-10-01 2012-02-14 Isis Innovation, Ltd. Immunotoxin derived from a recombinant human autoantibody and method of using thereof
WO2006076417A1 (en) 2005-01-12 2006-07-20 Proteonova, Inc. Method for making targeted therapeutic agents
US9603911B2 (en) * 2013-03-14 2017-03-28 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins

Also Published As

Publication number Publication date
WO2014158770A1 (en) 2014-10-02
US9976131B2 (en) 2018-05-22
SI2971038T1 (sl) 2020-02-28
CA2903252A1 (en) 2014-10-02
EP2971038A1 (en) 2016-01-20
DK2971038T3 (da) 2020-01-27
PT2971038T (pt) 2020-01-20
EP2971038A4 (en) 2016-11-23
US9603911B2 (en) 2017-03-28
CA2903252C (en) 2023-01-17
AU2014241891A1 (en) 2015-09-17
PL2971038T3 (pl) 2020-04-30
AU2014241891B2 (en) 2017-09-14
ES2765302T3 (es) 2020-06-08
US20160106819A1 (en) 2016-04-21
JP2016512251A (ja) 2016-04-25
EP2971038B1 (en) 2019-12-04
US20170204387A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
JP7442879B2 (ja) Ｍｈｃクラスｉエピトープ送達ポリペプチド
JP7054948B2 (ja) プロテアーゼ切断耐性、志賀毒素ａサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子
Scobie et al. A soluble receptor decoy protects rats against anthrax lethal toxin challenge
US10519210B2 (en) Multi-level specific targeting of cancer cells
CN108948177A (zh) 融合分子与il-15变异体
US9976131B2 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EP3256166A1 (en) Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CN113528569B (zh) 一种利用isPLA高通量筛选单域抗体的方法及其应用
WO2017053290A1 (en) Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
Habibi et al. Expression of a chimeric protein containing the catalytic domain of shiga-like toxin and human granulocyte macrophage colony-stimulating factor (Hgm-csf) IN Escherichia coli and its recognition by reciprocal antibodies
de Moura Biotechnological Application of AIP56, an AB-toxin from Photobacterium Damselae Subsp. Piscicida
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
Loftis Re-targeting of anthrax toxin binding for immunomodulation and targeted cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170302

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170302

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170829

R150 Certificate of patent or registration of utility model

Ref document number: 6203372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250